证券代码：688578 证券简称：艾力斯 公告编号：2025-016 上海艾力斯医药科技股份有限公司 关于公司股东减持股份计划公告 股东上海艾祥企业发展中心（有限合伙）、南通艾耘企业发展中心（有限合 伙）保证向上海艾力斯医药科技股份有限公司提供的信息不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 公司董事会及全体董事保证公告内容与上述股东提供的信息一致。 重要内容提示： 股东持股的基本情况 截至本公告披露日，员工持股平台上海艾祥企业发展中心（有限合伙）（以 下简称"上海艾祥"）、南通艾耘企业发展中心（有限合伙）（以下简称"南通艾耘"， 上海艾祥、南通艾耘合称"员工持股平台"）分别持有上海艾力斯医药科技股份有 限公司（以下简称"公司"或"艾力斯"）股份 32,930,660 股、9,770,362 股，占公司 总股本 7.32%、2.17%，为其于公司首次公开发行前取得的股份，且已于 2023 年 12 月 4 日起上市流通。 减持计划的主要内容 员工持股平台上海艾祥、南通艾耘计划拟通过大宗交易、集中竞价交易（含 盘后固定价格交易，下同）方式自 2025 年 9 月 ...

格隆汇8月8日丨艾力斯(688578.SH)公布，员工持股平台上海艾祥、南通艾耘计划拟通过大宗交易、集 中竞价交易（含盘后固定价格交易，下同）方式自2025年9月1日起3个月内减持其所持有的公司股份合 计不超过1350万股，拟减持股份占公司总股本的比例不超过3.00%。其中，通过集中竞价方式减持不超 过450万股，占公司总股本的比例不超过1.00%；通过大宗交易方式减持不超过900万股，占公司总股本 的比例不超过2.00%。减持价格依据市场价格确定。 ...

Core Viewpoint - The company Ailis (688578.SH) announced plans for a share reduction by its employee stock ownership platforms, indicating a potential shift in shareholder structure and liquidity in the market [1] Summary by Relevant Sections - **Share Reduction Plan** - The employee stock ownership platforms, Shanghai Aixiang Enterprise Development Center (Limited Partnership) and Nantong Aiyun Enterprise Development Center (Limited Partnership), plan to reduce their holdings starting from September 1, 2025, over a period of three months [1] - The total number of shares to be reduced is up to 13,500,000 shares, which represents no more than 3.00% of the company's total share capital [1]

人民财讯8月8日电，艾力斯(688578)8月8日晚间公告，员工持股平台上海艾祥、南通艾耘计划拟通过大 宗交易、集中竞价交易（含盘后固定价格交易）方式自2025年9月1日起3个月内减持其所持有的公司股 份合计不超过1350万股，拟减持股份占公司总股本的比例不超过3.00%。 转自：证券时报 ...

艾力斯公告，股东上海艾祥计划2025年9月1日至11月30日，通过集中竞价减持不超过347万股、大宗交 易减持不超过694万股，合计不超过1041万股，占公司总股本2.31%；股东南通艾耘同期通过集中竞价 减持不超过103万股、大宗交易减持不超过206万股，合计不超过309万股，占公司总股本0.69%。 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative return of over 20% within the next six months [6]. Core Insights - The company reported a total revenue of 657 million yuan for H1 2025, representing a year-on-year growth of 20%, with a net profit of 328 million yuan, up 59% [1]. - The company has successfully reduced R&D expenses to 228 million yuan, with an R&D expense ratio of 37.25%, down 6 percentage points year-on-year [2]. - The drug Pimiatinib has shown potential as a breakthrough therapy, with a 54% overall response rate (ORR) in a clinical trial, significantly higher than the 3.2% in the placebo group [3]. - The company has initiated a clinical study for ABSK011, a drug targeting FGFR4, which has received breakthrough therapy designation, indicating its potential in treating HCC patients with FGF19 overexpression [4]. - The company is actively developing several pipeline drugs, including ABSK043 and ABSK061, with promising early data [5]. Financial Projections - The company is projected to achieve revenues of 630 million yuan, 684 million yuan, and 634 million yuan for the years 2025, 2026, and 2027, respectively [6]. - The expected net profit for the same years is forecasted to be 45 million yuan, 68 million yuan, and 98 million yuan [6].

Core Viewpoint - MSCI announced the results of its quarterly index review, which includes the addition and removal of several stocks in the MSCI China Index and MSCI Global Standard Index, effective after market close on August 26 [1][7]. Group 1: New Additions to MSCI China Index - The MSCI China Index added 14 stocks, including Horizon Robotics-W, Lao Pu Gold, NetEase Cloud Music, Sangfor Technologies, and Citic Bank [1][3]. - Among the newly added stocks, Citic Bank is the largest by market capitalization in the MSCI Emerging Markets Index [1]. Group 2: Stocks Removed from MSCI China Index - A total of 17 stocks were removed from the MSCI China Index, including Yingjia Gongjiu, Oriental Yuhong, Supor, and Hisense Home Appliances [1][9][10]. Group 3: Implications of Index Changes - The inclusion of new stocks in the MSCI China Index is expected to attract significant passive investment flows on the effective date [7]. - The MSCI China A-Shares Onshore Index also saw adjustments, adding five stocks, including Citic Bank and Giant Network [10].

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary of CFOs in the chemical preparation sector of A-shares is 1.0448 million yuan [1] - The age distribution of CFOs shows that those aged 40-50 constitute 47% of the market, while those aged 60 and above account for only 4% [1] Group 2 - The top three highest-paid CFOs are Lü Hongbin from Dize Pharmaceutical with 4.2101 million yuan, Si Yanzha from Lizhu Group with 3.904 million yuan, and Lai Dequ from Kelun Pharmaceutical with 3 million yuan [2] - The largest salary decrease was observed for Xu Rongyi from Hainan Haiyao, with a year-on-year decline of 48.66% [2] - The highest salary increase was recorded for Wang Lin from Ailis, with a year-on-year increase of 104.6% [2]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary of CFOs in the chemical preparation sector of A-share companies is 1.0448 million yuan [1] - The age distribution of CFOs shows that those aged 40-50 constitute 47% of the market, while those aged 60 and above account for only 4% [1] Group 2 - The top three highest-paid CFOs are Lü Hongbin from Dize Pharmaceutical with 4.2101 million yuan, Si Yanxia from Lizhu Group with 3.904 million yuan, and Lai Dequ from Kelun Pharmaceutical with 3 million yuan [2] - The largest salary decrease was observed for Xu Rongyi from Hainan Haiyao, with a year-on-year decline of 48.66% [2] - The highest salary increase was recorded for Wang Lin from Ailis, with a year-on-year increase of 104.6% [2]

Core Viewpoint - MSCI's latest quarterly index review includes the addition of 14 Chinese stocks and the removal of 17 existing constituents, effective after market close on August 26, 2025, reflecting a growing international interest in Chinese assets [1][3] Group 1: New Constituents - The new additions consist of 9 Hong Kong-listed companies and 5 A-share companies, with sectors including technology, innovative pharmaceuticals, and emerging consumer goods [1] - Notable Hong Kong additions include Horizon Robotics, Lao Pu Gold, NetEase Cloud Music, 3SBio, and Meitu, while A-share additions include Zhinan, CITIC Bank, Giant Network, Ailisi, and Jingwang Electronics [1] - Over 70% of the new constituents are from technology innovation and pharmaceutical research sectors, aligning with the strong performance of these sectors in the Hong Kong market [1] Group 2: Market Capitalization and Index Inclusion - CITIC Bank (A-share) and Lao Pu Gold (H-share) rank among the top three by market capitalization in the new MSCI Emerging Markets Index constituents [2] - CITIC Bank is included in both the MSCI China Index and the MSCI Emerging Markets Index, highlighting the allocation value of large-cap financial stocks in global index systems [2] - The selection process for the new constituents is based on MSCI's standardized quantitative screening methods, focusing on free float market capitalization, liquidity, and investability for foreign investors [2] Group 3: International Attention and Future Implications - The adjustment reflects a rising international focus on Chinese assets, with several foreign institutions upgrading their ratings for the Chinese stock market in 2025 [3] - Goldman Sachs maintains an overweight rating and raises the MSCI China Index target to 84 points, while Nomura Securities upgrades its rating to tactical overweight, particularly favoring technology sectors like AI and electric vehicles [3] - The inclusion of new constituents into global standard indices connects to approximately $12.5 trillion in international capital allocation needs, indicating a structural shift in market dynamics [3]